Insmed (INSM) Capital Expenditures (2011 - 2026)
Insmed (INSM) posted quarterly Capital Expenditures of $3.5 million for Q1 2026, down 65.44% year-over-year from $10.1 million in Q1 2025, and down 70.48% quarter-over-quarter from $11.8 million in Q4 2025.
Insmed (INSM) Capital Expenditures (2011 - 2026) Analysis & Trends
Insmed's Capital Expenditures history runs 16 years deep, the most recent figure standing at $3.5 million for Q1 2026.
- In Q1 2026, Capital Expenditures fell 65.44% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at -$4.5 million (down 316.01% YoY), while the FY2025 annual figure was $2.1 million, up 125.47% from the prior year.
- Capital Expenditures for Q1 2026 stood at $3.5 million, down from $11.8 million in the prior quarter.
- The five-year high for Capital Expenditures was $11.8 million in Q4 2025, with the low at -$23.2 million in Q3 2025.
- The 5-year median for Capital Expenditures is $3.4 million (2023), against an average of $1.2 million.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures sank 478.47% in 2024, then jumped 3124.02% in 2025.
- Insmed's Capital Expenditures stood at -$3.1 million in 2022, then soared by 168.46% to $2.2 million in 2023, then plunged by 225.87% to -$2.7 million in 2024, then soared by 534.94% to $11.8 million in 2025, then tumbled by 70.48% to $3.5 million in 2026.
- Business Quant data shows INSM's Capital Expenditures at $3.5 million in Q1 2026, $11.8 million in Q4 2025, and -$23.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.26 Mn |
| Jun 30, 2026 | 6.26 Mn |
| Mar 31, 2026 | 3.48 Mn |
| Mar 31, 2026 | 3.48 Mn |
| Dec 31, 2025 | 11.79 Mn |
| Dec 31, 2025 | 11.79 Mn |
| Sep 30, 2025 | -23.22 Mn |
| Sep 30, 2025 | -23.22 Mn |
| Jun 30, 2025 | 3.48 Mn |
| Jun 30, 2025 | 3.48 Mn |
| Mar 31, 2025 | 10.07 Mn |
| Mar 31, 2025 | 10.07 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Dec 31, 2024 | -2.71 Mn |
| Sep 30, 2024 | 10.07 Mn |
| Sep 30, 2024 | 10.07 Mn |
| Jun 30, 2024 | -15.37 Mn |
| Jun 30, 2024 | -15.37 Mn |
| Mar 31, 2024 | -333,000.00 |
| Mar 31, 2024 | -333,000.00 |